Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Welfo To Market Second-Line Anti-Malarial Drug Early In 2008 (India)

This article was originally published in PharmAsia News

Executive Summary

Welfo Pharmaceuticals of India plans to market a second-line malaria drug Maligo (dihydroartemisinin derivate) early next year. The company also says the drug is useful for patients who have become resistant to chloroquinine, the common malaria treatment. Other drugs with the same active ingredient are in use in India, but Maligo is considered most effective when combined with Holleykin Pharmaceuticals' anti-malarial drug, Artekin (piperaquine), already available in China. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts